Mass. Medicaid Holds Line Against GSK Line Extensions
Executive Summary
Prior authorization will be required by Massachusetts' Medicaid program for two GlaxoSmithKline antidepressant line extensions
You may also be interested in...
GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year
GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation
GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year
GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation
Crestor Impact Review To Precede Mass. Medicaid Preferred Statin Decision
Massachusetts Medicaid will assess the market impact of AstraZeneca's Crestor (rosuvastatin) before selecting a preferred statin for the program